Latest Commercialization News

Page 35 of 481
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.
Ada Torres
Ada Torres
26 Feb 2026
Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.
Victor Sage
Victor Sage
26 Feb 2026
AVADA Group Limited reported an 11% revenue increase to $101.5 million in H1 FY26, driven by strong growth in Queensland and New South Wales and early gains from its business transformation. Despite a statutory loss, adjusted EBITDA improved, setting the stage for a stronger second half.
Victor Sage
Victor Sage
26 Feb 2026
BrainChip Holdings Ltd reported a striking 374% jump in revenue for 2025, yet the company still posted a substantial operating loss of over US$20 million. The results reveal mixed signals for investors watching the semiconductor innovator’s path forward.
Sophie Babbage
Sophie Babbage
26 Feb 2026
Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.
Ada Torres
Ada Torres
26 Feb 2026
BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.
Sophie Babbage
Sophie Babbage
26 Feb 2026
Alpha HPA Limited reported a $22.5 million loss for the half-year ending December 2025, driven by ongoing investment in its HPA First Project. Despite the loss, strong demand from semiconductor and battery sectors and a recent $225 million capital raise position the company for significant growth.
Maxwell Dee
Maxwell Dee
26 Feb 2026
LDR Capital Property Fund has locked in a lease renewal with the Commonwealth Government at Garema Court, extending tenancy to 2030 and significantly reducing near-term leasing risk.
Eva Park
Eva Park
26 Feb 2026
Pilot Energy is advancing Australia’s first Direct Air Capture demonstration facility at its Cliff Head site, aiming to start operations by mid-2026 and pave the way for a large-scale carbon removal plant.
Maxwell Dee
Maxwell Dee
26 Feb 2026
NOVONIX Limited posted a $92.7 million net loss for 2025 while progressing its synthetic graphite anode materials business and preparing to divest its Battery Technology Solutions segment.
Maxwell Dee
Maxwell Dee
26 Feb 2026
Ovanti Limited announces a strategic leadership change in its US operations to boost its BNPL platform Flote’s commercialisation and prepare for a potential NASDAQ listing via SPAC.
Victor Sage
Victor Sage
26 Feb 2026